The National Pharmaceutical Council (NPC) in a blog post outlines why it has taken issue with the Institute for Clinical and Economic Review’s (ICER) proposed method for valuing single and short-term transformative therapies (SSTs).
ICER recently announced it was accepting stakeholder input on its proposed framework.
“While gene therapies or biopharmaceutical treatments might be top of mind when considering the definition of an SST, the definition should take all curative treatments, including devices, into account,” the blog post states. “ICER’s definition should also be clarified so it does not inadvertently include vaccines and anti-infective therapies.”
To read the full blog post on NPC’s website, click here.